LMWH Bemiparin and ULMWH RO-14 Reduce the Endothelial Angiogenic Features Elicited by Leukemia, Lung Cancer, or Breast Cancer Cells

REFERENCES

• Falanga A, Marchetti M, Vignoli A, Balducci D. Clotting mechanisms and cancer: implications in thrombus formation and tumor progression. Clin Adv Hematol Oncol 2003;1:673–678.
   PubMedGoogle Scholar
• Khorana AA, Streiff MB, Farge D, Mandalà M, Debourdeau P, Cajfinger F, Marty M, Falanga A, Lyman GH. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol 2009;27:4919–4926.
   PubMed Web of Science ®Google Scholar
• Gerotziafas GT, Papageorgiou C, Hatmi M, Samama MM, Elalamy I. Clinical studies with anticoagulants to improve survival in cancer patients. Pathophysiol Haemost Thromb 2008;36: 204–211.
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M. Heparin in tumor progression and metastatic dissemination. Semin Thromb Hemost 2007;33: 688–694.
   PubMed Web of Science ®Google Scholar
• Goerner A. The influence of anticlotting agents on transplantation and growth of tumor tissue. J Lab Clin Med 1930;16:369–372.
   Google Scholar
• Zacharski LR, Loynes JT. The heparins and cancer. Curr Opin Pulm Med 2002;8:379–382.
   PubMed Web of Science ®Google Scholar
• Coombe DR, Parish CR, Ramshaw IA, Snowden JM. Analysis of the inhibition of tumour metastasis by sulphated polysaccharides. Int J Cancer 1986;39:82–88.
   Web of Science ®Google Scholar
• Norrby K. Low-molecular-weight heparins and angiogenesis. Apmis 2006;114:79–102.
   PubMed Web of Science ®Google Scholar
• Khorana AA, Sahni A, Altland OD, Francis CW. Heparin inhibition of endothelial cell proliferation and organization is dependent on molecular weight. Arterioscler Thromb Vasc Biol 2003;23:2110–2115.
   PubMed Web of Science ®Google Scholar
• Marchetti M, Vignoli A, Russo L, Balducci D, Pagnoncelli M, Barbui T, Falanga A. Endothelial capillary tube formation and cell proliferation induced by tumor cells are affected by low molecular weight heparins and unfractionated heparin. Thromb Res 2008;121:637–645.
   PubMed Web of Science ®Google Scholar
• Kakkar VV, Balibrea JL, Martinez-Gonzalez J, Prandoni P, on behalf of the CANBESURE Study Group. Extended prophylaxis with bemiparin for prevention of venous thromboembolism after abdominal or pelvic surgery for cancer: the CANBESURE randomized study. J Thromb Haemost 2010;8:1223–1229.
   PubMed Web of Science ®Google Scholar
• Lecumberri R, Massuti B, Lopez Vivanco, Font A, Gonzalez Billalabeitia E, Rocha E, on behalf of the ABEL investigators, Adjuvant bemiparin in small cell lung cancer: results from the ABEL study [abstract]. Thromb Res 2010;125(Suppl. 2):S163.
   Google Scholar
• Gómez-Outes A, Lecumberri R, Pozo C, Rocha E. New anticoagulants: focus on venous thromboembolism. Curr Vasc Pharmacol 2009;7:309–329.
   PubMed Web of Science ®Google Scholar
• Antonijoan RM, Rico S, Puntes M, Borrell M, Fontcuberta J, Monreal M, Martinez-Gonzalez J, Barbanoj MJ. Pharmacokinetics and safety of a novel ultra low molecular weight heparin (RO-14) in healthy volunteers-a first time in human (FTIH) single ascending dose study [abstract]. J Thromb Haemost 2009;7(Suppl. 2):PP-WE-178.
   Google Scholar
• Heparins, Low-Molecular-Mass (0828), Ph. Eur. 6th Ed. Strasbourg, France: Directorate for the Quality of Medicines of the Council of Europe., 2008.
   Google Scholar
• Cailleau R, Olive M, Cruciger QV. Long-term human breast carcinoma cell lines of metastatic origin: preliminary characterization. In Vitro 1978;14:911–915.
   PubMedGoogle Scholar
• Zhang RD, Fidler IJ, Price JE. Relative malignant potential of human breast carcinoma cell lines established from pleural effusions and a brain metastasis. Invasion Metastasis 1991;11:204–215.
   PubMedGoogle Scholar
• Gazdar AF, Carney DN, Russell EK, Sims HL, Baylin SB, Bunn PAJ, Guccion JG, Minna JD. Establishment of continuous, clonable cultures of small-cell carcinoma of lung which have amine precursor uptake and decarboxylation cell properties. Cancer Res. 1980;40:3502–3507.
   PubMed Web of Science ®Google Scholar
• Falanga A, Marchetti M, Giovanelli S, Barbui T. All-trans-retinoic acid counteracts endothelial cell procoagulant activity induced by a human promyelocytic leukemia-derived cell line (NB4). Blood 1996;87:613–617.
   PubMed Web of Science ®Google Scholar
• Kuderer NM, Khorana AA, Lyman GH, Francis CW. A meta-analysis and systematic review of the efficacy and safety of anticoagulants as cancer treatment: impact on survival and bleeding complications. Cancer 2007;110:1149–1161.
   PubMed Web of Science ®Google Scholar
• Lazo-Langner A, Goss GD, Spaans JN, Rodger MA. The effect of low-molecular-weight heparin on cancer survival. A systematic review and meta-analysis of. J Thromb Haemost 2007;5:729–737.
   PubMed Web of Science ®Google Scholar
• Lee AYY. The roles of anticoagulants in patients with cancer. Thromb Res 2010;125(Suppl. 2):S8–S11.
   PubMedGoogle Scholar
• Mousa SA, Mohamed S. Inhibition of endothelial cell tube formation by the low molecular weight heparin, tinzaparin, is mediated by tissue factor pathway inhibitor. Thromb Haemost 2004;92:627–633.
   PubMed Web of Science ®Google Scholar
• Ludwig RJ. Therapeutic use of heparin beyond anticoagulation. Curr Drug Discov Technol 2009;6:281–289.
   PubMedGoogle Scholar
• Jayson GC, Gallagher JT. Heparin oligosaccharides: inhibitors of the biological activity of bFGF on Caco-2 cells. Br J Cancer 1997;75:9–16.
   PubMed Web of Science ®Google Scholar
• Hasan J, Shnyder SD, Clamp AR, McGown AT, Bicknell R, Presta M, Bibby M, Double J, Craig S, Leeming D, Stevenson K, Gallagher JT, Jayson GC. Heparin octasaccharides inhibit angiogenesis in vivo. Clin Cancer Res 2005;11:8172–8179.
   PubMed Web of Science ®Google Scholar
• Falanga A, Panova-Noeva M, Russo L. Procoagulant mechanisms in tumour cells. Best Practice Res Clin Haematol 2009;22:49–60.
   PubMed Web of Science ®Google Scholar
• Pérez-Ruiz A, Montes R, Carrasco P, Rocha E. Effects of a low molecular weight heparin, bemiparin, and unfractionated heparin on hemostatic properties of endothelium. Clin Appl Thromb Hemost 2002;8:65–71.
   PubMed Web of Science ®Google Scholar
• Westmuckett AD, Kakkar VV, Hamuro T, Lupu F, Lupu C. Bemiparin and fluid flow modulate the expression, activity and release of tissue factor pathway inhibitor, in human endothelial cells in vitro. Thrombosis Haemostasis 2001;86:1547–1554.
   PubMed Web of Science ®Google Scholar
• Vignoli A, Marchetti M, Balducci D, Barbui T, Falanga A. Differential effect of the low-molecular-weight heparin, dalteparin, and unfractionated heparin on microvascular endothelial cell hemostatic properties. Haematologica 2006;91:207–214.
   PubMed Web of Science ®Google Scholar